Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

RandomizEd Dabigatran Etexilate Dose Finding Study in Patients With Acute Coronary Syndromes Post Index Event With Additional Risk Factors for Cardiovascular Complications Also Receiving Aspirin and Clopidogrel: Multi-Centre Prospective Placebo Controlled Cohort Dose Escalation Study (RE-DEEM).

Trial Profile

RandomizEd Dabigatran Etexilate Dose Finding Study in Patients With Acute Coronary Syndromes Post Index Event With Additional Risk Factors for Cardiovascular Complications Also Receiving Aspirin and Clopidogrel: Multi-Centre Prospective Placebo Controlled Cohort Dose Escalation Study (RE-DEEM).

Completed
Phase of Trial: Phase II

Latest Information Update: 11 Sep 2014

At a glance

  • Drugs Dabigatran etexilate (Primary)
  • Indications Acute coronary syndromes; Cardiovascular disorders; Embolism and thrombosis
  • Focus Adverse reactions; Registrational
  • Acronyms RE-DEEM; RE-VOLUTION
  • Sponsors Boehringer Ingelheim Pharmaceuticals
  • Most Recent Events

    • 31 Aug 2018 Biomarkers information updated
    • 15 Mar 2012 Planned number of patients changed from 1878 to 2220 as reported by European Clinical Trials Database.
    • 07 May 2011 Results published in the European Heart Journal.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top